P osaconazole, marketed under the brand name Noxafil, was approved for use in the United States in September 2006. Since that time, this triazole antifungal's use has expanded in both the treatment and prevention of invasive fungal infections (IFI). Posaconazole exhibits antifungal abilities via inhibition of ergosterol synthesis-the main component of fungal cell membranes. It is currently indicated for use for prophylaxis of IFI due to Aspergillus or Candida species in neutropenic patients 13 years of age or older with myelodysplastic syndromes or acute myelogenous leukemia and hematopoietic stem-cell transplant recipients with significant graft-versus-host disease (GVHD). In addition, it is approved for treatment of oropharyngeal Candidiasis, including infections that are resistant to itraconazole or fluconazole. 1 IFI contribute substantially to the morbidity and mortality associated with severe and prolonged neutropenia resulting from intensive chemotherapy for hematologic malignancies and from the myeloablation used in allogeneic transplantation. Additionally, the development of GVHD puts allogeneic transplant recipients at high risk for a fungal infection. 2 Given the high mortality associated with IFI and our inability to reliably recognize active cases, it is not surprising that clinical studies focusing on fungal prophylaxis in highrisk patients are being conducted.
More than a decade ago, fluconazole prophylaxis was shown effective in preventing Candida infection in patients undergoing bone marrow transplantation. 3, 4 However, mold infections such as Aspergillus species and mucor species are not affected by fluconazole. The arrival of voriconazole in 2002 for the treatment of invasive Aspergillus infections heralded a new era in our ability to combat these diseases. However, data for antimold prophylaxis were still lacking. In 2004, a study comparing itraconazole with fluconazole as prophylaxis in patients receiving allogeneic stemcell transplants was published proving that antimold prophylaxis was potentially useful; however, the right drug for the job was still unavailable. 5 Then in 2007, the arrival of posaconazole was received with great fanfare as a new advance in the ability to prevent IFI in high-risk patients. 6, 7 The scientific community now has the results of two phase-3 studies of posaconazole prophylaxis to ponder, without the drug following the normal progression of being recognized as primary therapy for IFI. However, based on these data, posaconazole appears to be the drug of choice for prophylaxis in patients at high risk for the development of IFI, whereas voriconazole remains the preferred treatment for proven or probable aspergillosis. This then limits the options for empiric and salvage therapy to the echinocandins, various formulations of amphotericin B, and combination therapy.
In February 2008, the Infectious Disease Society of America released clinical practice guidelines detailing the treatment of aspergillosis. In these guidelines, posaconazole was recommended as the first-line agent for prophylaxis of IFI in the immunocompromised populations previously described. 8 Dosing for this indication is 200 mg orally 3 times daily. Recommendations for posaconazole use as alternative and/or salvage therapy for invasive aspergillosis were also included, although dosing in this subset is 200 mg orally 4 times daily.
Treatment of IFI is associated with significant increases in both length of stay (LOS) and hospital charges. [9] [10] [11] [12] Cost for treatment of IFI has been estimated from $49,000 to upwards of $100,000-depending on the agent(s) used in the diagnosis and treatment. Furthermore, additional LOS and utilization of hospital resources are also increased in patients with IFI.
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Posaconazole is available solely as an oral suspension. In March 2008, the average wholesale price of posaconazole was $634.79 per 105 mL bottle making the cost of prophylactic therapy approach $100 per day. IFI prophylaxis typically continues until patients are no longer neutropenic or are no longer receiving immunosuppressive chemotherapy regimens. Increased use of this agent is likely to have a corresponding impact on pharmacy budgets across the country. Although, when compared to the cost of treatment for IFI, prophylactic therapy cost is minimal.
